Key Drivers
- High Margins
- Strong Cash Flow
- Intangible Heavy
AIAI Summary
PTC should be viewed less as a scattered industrial software vendor and more as a focused platform compounder, but with the stock already pricing in strong execution at ~28x earnings, investors should only expect a durable re-rating if the deferred ARR pipeline converts into sustained growth and the AI/product-data thesis starts monetizing before 2027 rather than slipping on enterprise approval delays.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High Margins
- •Strong Cash Flow
- •Intangible Heavy
PTC delivered strong software-like margins and cash flow with solid leverage and capital returns, but heavy intangibles and a stretched valuation temper the otherwise positive operating profile.
Price Behavior
Key Price Behavior Insights:
- •Higher-lows pattern
- •Choppy rebound
- •Resistance overhead
PTC is in a modestly positive last-month trend, with $136-$137 acting as support and $146.65-$147.65 capping upside.
Brief dip to $136.76 before rebounding, showing choppy momentum
Sentiment & News
Key News Insights:
- •Software demand
- •Buyback boost
- •Clinical catalysts
PTC Inc. is benefiting from strong software demand, major customer wins and buybacks, while PTC Therapeutics is seeing revenue and pipeline momentum tempered by mixed clinical-data reactions.
Overall, the news trend is constructive for PTC, with operational strength and capital returns supporting PTC Inc. and upcoming product and trial milestones driving PTC Therapeutics
Similar Companies in Technology
Other companies in the same sector with AI ratings